Adjunctive perampanel for glioma-associated epilepsy

Publication date: Available online 9 October 2018Source: Epilepsy & Behavior Case ReportsAuthor(s): Anastasie M. Dunn-Pirio, Sarah Woodring, Eric Lipp, James E. Herndon, Patrick Healy, Mallika Weant, Dina Randazzo, Annick Desjardins, Henry S. Friedman, Katherine B. PetersAbstractGlioma-associated epilepsy is associated with excessive glutamate signaling. We hypothesized that perampanel, an amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-type glutamate receptor antagonist, would treat glioma-related epilepsy. We conducted a single-arm study of adjunctive perampanel for patients with focal-onset glioma-associated seizures. The most common related adverse events were fatigue and dizziness. Three out of 8 participants had patient-reported seizure reduction and an additional 3 had improved control. Of these 6, 5 had isocitrate dehydrogenase 1 mutant gliomas. We conclude that perampanel is safe for patients with glioma-related focal-onset epilepsy. Further study into the association of AMPA signaling to IDH1 status and seizures is warranted.

Source: Epilepsy and Behavior Case Reports - October 10, 2018 Category: Neurology Source Type: research